217 related articles for article (PubMed ID: 34659125)
1. Predictive Modeling of MAFLD Based on Hsp90α and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model.
Xie Y; Chen L; Xu Z; Li C; Ni Y; Hou M; Chen L; Chang H; Yang Y; Wang H; He R; Chen R; Qian L; Luo Y; Zhang Y; Li N; Zhu Y; Ji M; Liu Y
Front Endocrinol (Lausanne); 2021; 12():743202. PubMed ID: 34659125
[TBL] [Abstract][Full Text] [Related]
2. Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria.
Kolawole OJ; Oje MM; Betiku OA; Ijarotimi O; Adekanle O; Ndububa DA
BMC Gastroenterol; 2024 May; 24(1):147. PubMed ID: 38724942
[TBL] [Abstract][Full Text] [Related]
3. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis.
Ke Y; Liu S; Zhang Z; Hu J
Lipids Health Dis; 2021 May; 20(1):55. PubMed ID: 34034750
[TBL] [Abstract][Full Text] [Related]
4. Geranylgeranylacetone induction of HSP90α exerts cryoprotective effect on Acipenser sinensis sperm.
Xi MD; Li P; Du H; Qiao XM; Liu ZG; Wei WQ
Anim Reprod Sci; 2018 Jun; 193():19-25. PubMed ID: 29724523
[TBL] [Abstract][Full Text] [Related]
5. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease.
Yan S; Zhang S; Du A; Miao H; Lu B; Huang Z; Ji L
Phytomedicine; 2021 Oct; 91():153666. PubMed ID: 34339944
[TBL] [Abstract][Full Text] [Related]
6. [Applied research of ultrasound attenuation parameter in the diagnosis of metabolic dysfunction-associated fatty liver disease].
Hou MM; Yuan XW; Wang YQ; Zhang Y; Zhang SY; Yu SH; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):290-296. PubMed ID: 35462485
[No Abstract] [Full Text] [Related]
7. Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial.
Fu Y; Xu X; Huang D; Cui D; Liu L; Liu J; He Z; Liu J; Zheng S; Luo Y
EBioMedicine; 2017 Oct; 24():56-63. PubMed ID: 28939487
[TBL] [Abstract][Full Text] [Related]
8. Circulating Hsp90 Isoform Levels in Overweight and Obese Children and the Relation to Nonalcoholic Fatty Liver Disease: Results from a Cross-Sectional Study.
Bălănescu A; Stan I; Codreanu I; Comănici V; Bălănescu E; Bălănescu P
Dis Markers; 2019; 2019():9560247. PubMed ID: 31885746
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of the Chinese Visceral Adiposity Index for Metabolic Dysfunction-Associated Fatty Liver Disease and Elevated Alanine Aminotransferase Levels in Nonobese Chinese Adults: A Cross-Sectional Study.
Niu Z; Chen J; Wang H; Wang R; Peng H; Duan S; Yao S
J Inflamm Res; 2024; 17():3893-3913. PubMed ID: 38915805
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
12. A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic.
Liu W; Li J; Zhang P; Hou Q; Feng S; Liu L; Cui D; Shi H; Fu Y; Luo Y
Cancer Sci; 2019 Sep; 110(9):2941-2959. PubMed ID: 31343810
[TBL] [Abstract][Full Text] [Related]
13. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
15. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
Liu Y; Liu S; Huang J; Zhu Y; Lin S
J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
[TBL] [Abstract][Full Text] [Related]
16. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.
Honda T; Ishigami M; Luo F; Lingyun M; Ishizu Y; Kuzuya T; Hayashi K; Nakano I; Ishikawa T; Feng GG; Katano Y; Kohama T; Kitaura Y; Shimomura Y; Goto H; Hirooka Y
Metabolism; 2017 Apr; 69():177-187. PubMed ID: 28285648
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
19. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
